H. Lundbeck A/S/€HLUNB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About H. Lundbeck A/S
H. Lundbeck A/S is a Danish pharmaceutical company focused on the research, development, production, and marketing of pharmaceuticals for the treatment of brain disorders. Headquartered in Copenhagen, Denmark, Lundbeck's core business includes a portfolio of products addressing conditions such as depression, anxiety, schizophrenia, Alzheimer's disease, and Parkinson's disease. The company has a significant presence in the neuropharmaceuticals industry, striving to deliver innovative solutions to patients with unmet medical needs. Lundbeck operates internationally, distributing its products across multiple markets, supported by its strategic positioning in research and development. Unique competitive strengths include its dedicated focus on central nervous system disorders and ongoing investments in innovative therapies.
- Ticker
- €HLUNB
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 5,000
- Headquarters
- Valby, Denmark
- Website
- www.lundbeck.com
H. Lundbeck A/S Metrics
BasicAdvanced
€7.1B
13.72
€0.53
0.26
€0.15
2.11%
Price and volume
Market cap
€7.1B
Beta
0.26
52-week high
€7.01
52-week low
€4.75
Average daily volume
835K
Dividend rate
€0.15
Financial strength
Current ratio
1.367
Quick ratio
0.899
Long term debt to equity
0.348
Total debt to equity
0.351
Dividend payout ratio (TTM)
29.00%
Interest coverage (TTM)
405.50%
Profitability
EBITDA (TTM)
1,106.443
Gross margin (TTM)
82.06%
Net profit margin (TTM)
15.16%
Operating margin (TTM)
24.99%
Effective tax rate (TTM)
27.65%
Revenue per employee (TTM)
€694,370
Management effectiveness
Return on assets (TTM)
7.76%
Return on equity (TTM)
15.41%
Valuation
Price to earnings (TTM)
13.722
Price to revenue (TTM)
2.08
Price to book
1.98
Price to tangible book (TTM)
-5.8
Price to free cash flow (TTM)
10.473
Free cash flow yield (TTM)
9.55%
Free cash flow per share (TTM)
0.695
Dividend yield (TTM)
2.11%
Forward dividend yield
2.11%
Growth
Revenue change (TTM)
10.37%
Earnings per share change (TTM)
14.67%
3-year revenue growth (CAGR)
10.23%
10-year revenue growth (CAGR)
5.69%
3-year earnings per share growth (CAGR)
16.68%
10-year earnings per share growth (CAGR)
11.72%
3-year dividend per share growth (CAGR)
25.63%
What the Analysts think about H. Lundbeck A/S
Analyst ratings (Buy, Hold, Sell) for H. Lundbeck A/S stock.
Analyst projections of the future price of H. Lundbeck A/S stock.
Bulls say / Bears say
Revenue grew 16% at constant exchange rates in H1 2026, or 13% after removing a one-off inventory build, with Vyepti and Rexulti driving demand. Management maintained its upgraded full-year guidance and said performance was tracking towards its upper end. (H. Lundbeck A/S)
Lundbeck has advanced bexicaserin into the next stage of testing for severe epilepsies: its two Phase III studies have completed randomisation, and the drug has FDA Breakthrough Therapy designation. Positive trial results could open a new growth avenue, although efficacy is not yet established. (PR Newswire, PR Newswire)
The balance sheet is improving: net debt fell to DKK 7.4 billion and net debt to adjusted EBITDA dropped to 1.0 times from 1.8 times a year earlier. That gives Lundbeck more room to fund research and development and manage its upcoming patent expiries. (Quartr)
Several major products face looming loss of exclusivity: Abilify and Brintellix in 2026–27, followed by Rexulti in 2029. Bank analysts see the expiries as a threat to sales growth and expect pressure on revenue later in the decade. (Investing.com, Hilo Research)
The H1 headline profit growth overstates the underlying improvement: after excluding the one-off inventory build, adjusted EBITDA rose only 3% in Danish kroner, while research and development costs increased as pipeline trials advanced. Higher investment and costs could limit near-term profit conversion from sales growth. (H. Lundbeck A/S)
Foreign exchange could substantially dilute reported growth: at current rates, Lundbeck said full-year revenue growth may be about four percentage points lower than its constant-currency outlook, and adjusted EBITDA growth about eight points lower. This creates a risk that strong underlying trading translates into weaker reported results. (H. Lundbeck A/S)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
H. Lundbeck A/S Financial Performance
Revenues and expenses
H. Lundbeck A/S Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing H. Lundbeck A/S
AllEURUSDGBP
Fund name | Fund size | €HLUNB weighting |
|---|---|---|
Vanguard ESG Developed Europe All Cap£V3EA | €125M | 0.02% |
Vanguard ESG Developed Europe All Cap£V3EL | €35M | 0.02% |
Vanguard FTSE Developed Europe ex UK$VERE | €1.4B | 0.02% |
Vanguard FTSE Developed Europe ex UK€VERX | €3.3B | 0.02% |
Vanguard FTSE Developed Europe ex UK£VERX | €3.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.